We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

BBI Solutions Showcases Mobile Solutions Capabilities at AACC 2019

By LabMedica International staff writers
Posted on 06 Aug 2019
Print article
Image: The Novarum mobile app enables rapid POCT using just a smartphone (Photo courtesy of BBI Solutions).
Image: The Novarum mobile app enables rapid POCT using just a smartphone (Photo courtesy of BBI Solutions).
BBI Solutions (Crumlin, UK) demonstrated how its lateral flow software is making point-of-care testing (POCT) more accurate, efficient and easier to use than ever before at the world’s largest laboratory medicine trade show, American Association for Clinical Chemistry (AACC) exhibition.

BBI Solutions are leading experts in immunoassay development & manufacturing services, offering an extensive portfolio of diagnostic products globally. At the AACC Clinical Lab Expo, BBI’s mobile arm, Novarum, launched a demonstrator app that can read the results of an imitated malaria test. Novarum is an easy-to-use mobile app enabling rapid POCT, using just a smartphone. Novarum’s technology accurately interprets the results of lateral flow assays while offering test choreography and tracking disease outbreaks, providing clients with a competitive advantage within the diagnostic landscape. At the tradeshow, the company demonstrated how mobile technology can remove complexities from lateral flow testing to enable healthcare professionals or patients to deliver lab quality results in the field.

Novarum’s innovative mobile technology mitigates the risks identified around lateral flow by the Clinical Laboratory Improvement Amendments (CLIA), which establishes quality standards for all laboratory testing to ensure the accuracy, reliability and timeliness of patient test results. The company demonstrated every aspect of its immunoassay development - feasibility and planning, reagent supply and manufacturing, custom antibody development, custom conjugations, lateral flow development and manufacturing, as well as Novarum’s smartphone reader capability which enables immediate, POC diagnosis.

“This is an exciting opportunity to, once again, showcase BBI Solutions’ comprehensive suite of capabilities at the AACC expo. We’re particularly excited to be launching our demo app at the event this year, which enables us to demonstrate every aspect of Novarum’s capability that a potential customer could include in a custom-built app,” said John Hanson, Chief Commercial Officer at BBI Solutions. “We want to help our customers envision what it would be like for the healthcare professional or patient using the test and to highlight how Novarum’s software mitigates the risks identified around lateral flow testing.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more